

Data Sheet

 Product Name:
 Compound E

 Cat. No.:
 CS-0003250

 CAS No.:
 209986-17-4

 Molecular Formula:
 C27H24F2N4O3

Molecular Weight: 490.50

Target: v-secretase

Pathway:Neuronal Signaling; Stem Cell/WntSolubility:DMSO : 100 mg/mL (ultrasonic)

BIOLOGICAL ACTIVITY:

Compound E is a **γ-secretase** inhibitor. Compound E bloks β -amyloid(40), β -amyloid(42), and Notch γ -secretase cleavage with **IC**₅₀s of 0.24, 0.37, 0.32 nM, respectively. IC50 & Target: IC50: 0.24 nM (β -amyloid(40)), 0.37 nM (β -amyloid(42)), 0.24 nM (Notch)^[1] *In Vitro:* Compound E reduces the proliferation of T47D, and MCF-7 cell lines by less than 50% at a concentration of 50 μ M^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: Compound E is prepared and diluted in DMSO^[1]. The breast cancer cell lines MDA-MB-231, T47D, and MCF-7 are treated with Compound E at concentrations in the range 0.01-50 μ M for 48 h and their viability is determined using a Coulter counter [1].

References:

[1]. Beher D, et al. Pharmacological knock-down of the presentilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presentilin biology. J Biol Chem. 2001 Nov 30;276(48):45394-402.

[2]. Rasul S, et al. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer. 2009 Jun 16;100(12):1879-88.

CAIndexNames:

Benzeneacetamide, N-[(1S)-2-[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-

SMILES:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr., Suite Q., Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com